Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribavirin pharmacokinetics in adults treated for Lassa fever
ISRCTN11104750Phase 4Completed
- Sponsor
- Bernhard Nocht Institute for Tropical Medicine
- Start
- Feb 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ribavirin in Lassa fever, sponsored by Bernhard Nocht Institute for Tropical Medicine. Primary endpoint: Ribavirin pharmacokinetic parameters. Started Feb 2020; status: completed.
02
Drugs
ribavirin
03
Conditions
Lassa fever
Beyond the preview
Go deeper on ISRCTN11104750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11104750.